Abstract
Background: Impairment of platelet response to antiaggregatory agents is seen in individuals with central obesity and may play a role in the increased cardiovascular risk associated with obesity. In this study we evaluated whether this impairment involves the antiaggregatory pathways regulated by cAMP and cGMP.
Methods: We obtained platelet-rich plasma from 12 obese individuals and 12 controls. We investigated the effects of the cyclic nucleotide analogs 8-pCPT-cAMP (10–500 μmol/L) and 8-pCPT-cGMP (10–500 μmol/L) on ADP-induced platelet aggregation as assessed by decreased light scattering. We assessed the activation of cAMP- and cGMP-dependent protein kinases by measuring phosphorylation of the vasodilator-stimulated phosphoprotein (VASP) at Ser157 and Ser239.
Results: The antiaggregatory effect of both cyclic nucleotide analogs was impaired in obese individuals compared to controls, with mean (SE) half-maximal inhibitory concentrations (IC50) (after 20-min incubation) of 123 (33) μmol/L vs 5 (1) μmol/L, respectively, for 8-pCPT-cAMP (P <0.01) and of 172 (43) μmol/L vs 17 (8) μmol/L, respectively, for 8-pCPT-cGMP (P <0.01). The Homeostasis Model Assessment Index of Insulin Resistance was independently correlated with cyclic nucleotide analog IC50. In obese individuals, VASP phosphorylation at Ser157 and Ser239 in response to cyclic nucleotides was significantly lower than in controls.
Conclusions: In central obesity the reduced ability of cyclic nucleotides to inhibit platelet aggregation is associated with reduced activation of their specific kinases. Because cyclic nucleotides help regulate platelet antiaggregation, alteration of this ability is consistent with platelet hyperactivity in obesity.
Central obesity is a major risk factor for early cardiovascular events and other atherothrombotic diseases (1)(2). It is associated with insulin resistance, lipid disorders, oxidative stress, and low-grade chronic inflammation as well as with a prothrombotic state (1)(2). For this reason, central obesity has been considered in the recent classification of the International Diabetes Federation as a necessary component of the metabolic syndrome (3), a cluster of cardiovascular risk factors.
One possible mechanism contributing to enhanced thrombotic risk in obese patients is platelet hyperactivation, which is involved in the different steps of the atherosclerotic process (4)(5).
Our previous studies of platelets of obese persons identified multiple defects in the sensitivity to the antiaggregatory mediators. In particular, we observed reduction of the antiaggregatory effects of insulin and organic nitrates, which activate the cGMP pathway (6)(7)(8)(9), and of adenosine and prostacyclin, which activate the cAMP pathway (10)(11). We also observed reduced sensitivity to the antiaggregatory effects of cGMP and cAMP themselves, which are the main intracellular messengers responsible for inhibition of platelet responses elicited by the large majority of platelet agonists (11).
Platelet response to cyclic nucleotides is complex and depends on nucleotide concentrations and the time-course of platelet exposure. Most authors agree that the main effect of cyclic nucleotides is inhibitory and is exerted through activation of the corresponding cyclic nucleotide-dependent protein kinases, i.e., protein kinase G (PKG)1 for cGMP and protein kinase A (PKA) for cAMP (12)(13)(14)(15)(16), which are involved in the regulation of basic mechanisms of platelet activation, such as agonist-induced increases of cytosolic calcium (12)(15)(16)(17), fibrinogen binding (18), and cytoskeleton protein contraction (19). Recent evidence indicates, however, that increased concentrations of platelet cGMP are associated with enhanced platelet function (20)(21).
A relevant target of both cyclic nucleotide-regulated protein kinases is the focal adhesion protein vasodilator-stimulated phosphoprotein (VASP) (22)(23), which is strategically involved in platelet inhibitory pathways. VASP phosphorylation closely correlates with inhibition of fibrinogen binding to glycoprotein IIb/IIIa (GP IIb/IIIa) (18)(24), and it affects initial sequences of platelet adhesion and activation by modulating interactions of platelet actin filaments (4)(19). VASP is considered a reliable mediator of cyclic nucleotide action (12)(24)(25).
The reduced platelet antiaggregatory activity exerted by both cyclic nucleotides (11) does not necessarily lead to impaired activation of cyclic nucleotide/specific kinase/VASP pathways. Platelets from individuals with insulin resistance have higher free cytoplasmic calcium concentrations than platelets from controls (26); thus, calcium fluxes may present a primitive resistance that is also inhibited by efficient cyclic nucleotide/specific kinase/VASP pathways. The aim of these studies was to clarify whether cyclic nucleotides activate downstream pathways in individuals with central obesity, as they do in lean controls.
Patients and Methods
study participants
The study participants were 12 healthy volunteers [6 men and 6 women, mean (SE) age 34.7 (1.9) years] and 12 individuals with central obesity [6 men and 6 women, age 35.4 (2.1) years]. The criterion for central obesity was a waist circumference, measured at its smallest point with the abdomen relaxed, >88 cm in women or >102 cm in men (27). All study participants gave informed consent before investigation and the Ethics Committee of our Department approved the study design. None of the study participants had smoked or taken medications that could influence platelet function during the previous 4 weeks. Obese participants were otherwise healthy on the basis of medical history, physical examination, and standard diagnostic procedures; had no family history of diabetes mellitus; were normotensive (i.e., arterial blood pressure value <140/90 mm Hg); and had fasting and postchallenge plasma glucose concentrations within reference intervals [fasting plasma glucose ≤6.105 mmol/L (110 mg/dL) and plasma glucose <7.77 mmol/L (140 mg/dL) 2 h after a 75-g oral glucose load]. Biochemical variables were measured as described below.
study design
In previous investigations we used 8-bromo analogs of cyclic nucleotides, which because of their hydrophilicity are poorly permeable through cell membranes (11). In this study we used the more lipophilic molecules 8-(4-Chlorophenylthio)-cAMP (8-pCPT-cAMP) and 8-(4-Chlorophenylthio)-cGMP (8-pCPT-cGMP), which are highly effective in PKA and PKG activation (28) and do not interfere with cyclic nucleotide phosphodiesterases (28); because these analogs have not been previously used in studies of platelets from obese individuals, we also evaluated whether their antiaggregatory effect is decreased in central obesity.
For platelets from both lean and obese study participants, we investigated (a) sensitivity to the antiaggregatory effects of the cyclic nucleotide analogs 8-pCPT-cAMP and 8-pCPT-cGMP on ADP-induced platelet aggregation; (b) PKA and PKG concentrations; and (c) concentrations of total VASP and of VASP phosphorylation in response to 8-pCPT-cAMP and 8-pCPT-cGMP.
biochemical variables
Fasting venous plasma glucose, serum cholesterol, HDL cholesterol, and triglycerides were measured by automated chemical analyses in the central laboratory of our hospital. Fasting plasma insulin was measured by RIA with a reagent set from Biochem Immuno System S.p.A.; the cross-reactivity was 100% for human insulin, 14% for human proinsulin, and 0.0002% for C-peptide and glucagon. Fasting C-peptide was measured by RIA with a reagent set from Biochem Immuno System S.p.A.; the cross-reactivity was 100% for human C peptide, 3.2% for human proinsulin, and absent for glucagon. Insulin sensitivity in the fasting state was estimated with the Homeostasis Model Assessment Index of Insulin Resistance (HOMA IR) according to the following formula: fasting plasma glucose (mmol/L) × fasting serum insulin (μU/mL) divided by 22.5 (29). HOMA IR is commonly used in clinical studies as a marker of insulin resistance (30)(31); high HOMA IR scores denote low insulin sensitivity.
platelet aggregation studies
Blood samples were collected after study participants had fasted overnight. A venous blood sample was collected without stasis and anticoagulated with 1 volume of sodium citrate, 38 g/L, pH 7.4, to 9 volumes of blood. Platelet-rich plasma (PRP) was obtained from citrated whole blood by 20-min centrifugation at 100g at room temperature; platelet-poor plasma (PPP) was prepared by further centrifugation at 2000g for 10 min. Platelet counts were determined on an S-plus Coulter Counter (Coulter Electronics). Mean (SE) platelet counts in PRP (109/L) were 268 (25) in controls and 248 (18) in obese individuals (not significant). Because the study design consisted of measurement of platelet responses in samples from the same PRP after addition of buffer solutions or different substances for each study participant, platelet numbers were not adjusted. Platelet aggregation was carried out by following light-scattering changes as originally described by Born (32), using a model 500 Chrono Log aggregometer at a constant stirring speed of 900 rpm.
Platelet aggregation in response to ADP was reported as maximal aggregation, calculated as: 100 × [(initial absorbance − absorbance after addition of ADP)/(initial absorbance)], with ADP added at a final concentration of 4 μmol/L. Half-maximal inhibitory concentration (IC50) values of the 2 cyclic nucleotide analogs were determined at the different incubation times, when possible.
protein content of pka and pkg
PKA and PKG concentrations were determined by Western blotting as previously described by Dey et al. (33). Experiments were carried out in 50-mL blood samples antiaggregated with acid citrate-dextrose solution (vol/vol:1/6). ACD-anticoagulated PRP, obtained by centrifugation at 100g for 20 min, underwent further centrifugation at 2000g for 10 min. The pellet was washed 2 times at 37 °C in HEPES-Na buffer (10 mmol/L HEPES Na, 140 mmol/L NaCl, 2.1 mmol/L MgSO4, 10 mmol/L D-glucose, pH 7.4); 500 μL of washed platelets (2.5 × 109 platelets/mL) were sedimented by centrifugation at 2000g for 10 min and solubilized by lysis buffer (1% SDS, 0.1% Triton X-100, 10 mmol/L Tris-HCl, pH 7.4), supplemented with protease inhibitors (Sigma). After centrifugation at 30 000g for 60 min, 30 μg protein from platelet lysates was subjected to 8% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then transferred to polyvinylidenedifluoride membrane (Millipore). Membranes were incubated at room temperature for 1 h with rabbit polyclonal antibodies against PKA 1α/1β (Santa Cruz Biotechnology; 1:3000), or rabbit polyclonal antibodies against PKG 1α/1β (Calbiochem; 1:300). Then, membranes were washed 3 times for 10 min each with PBS (136 mmol/L NaCl, 2.7 mmol/L KCl, 10 mmol/L NaHPO4, 1.8 mmol/L KH2PO4)/0.1% Tween-20 (PBS-Tween) and incubated with antirabbit horseradish peroxidase-conjugated secondary antibody (1:10 000) for 45 min. After 3 final washes (10 min each) in PBS-Tween, membranes were subjected to chemiluminescence (Amersham Life Sciences) for detection of the specific antigen. Density of bands in Western blots was analyzed with Kodak 1D Image Analysis software.
protein content of vasp and vasp phosphorylation in response to analogs of camp and cgmp
PKA preferentially induces VASP phophorylation at Ser157 causing an upward shift in the apparent molecular weight from 46 kDa to 50 kDa in sodium dodecyl sulfate-polyacrylamide gel electrophoresis, whereas PKG preferentially induces VASP phosphorylation at Ser239 without any change in molecular mass (22)(23).
Experiments were carried out in blood samples anticoagulated with ACD and washed platelets prepared as previously described; 500 μL of washed platelets containing 2.5 × 109 platelets/mL were preincubated in the presence of 8-pCPT-cAMP (10–500 μmol/L), 8-pCPT-cGMP (10–500 μmol/L), or buffer solution for 10 min. Platelets were then sedimented by centrifugation at 2000g for 10 min, solubilized, and subjected to Western blot analysis as described previously.
The incubation of membranes was carried out with the following antibodies (all obtained from Calbiochem): rabbit antihuman VASP protein (1:15 000); monoclonal antibody recognizing VASP phosphorylated at Ser157 (1:1000); and monoclonal antibody recognizing VASP phosphorylated at Ser239 (1:1000).
After 3 washes in PBS-Tween, membranes were incubated for 45 min with monoclonal antirabbit horseradish peroxidase-conjugated secondary antibody (1:10 000) for VASP protein detection or with horseradish peroxidase-conjugated rabbit antimouse IgG (1:50 000) for phosphorylated VASP detection. After additional washes, protein expression was visualized as described previously.
chemicals
ADP, 8-pCPT-cAMP, 8-pCPT-cGMP, PBS, and Tween-20 were obtained from Sigma. The source of the specific antibodies for Western blotting has been previously indicated.
statistical analysis
Data in the text and in the Figs. are expressed as mean (SE). Statistical analyses were performed with ANOVA for repeated measurements, and, when appropriate, by the Student t-test for unpaired data. IC50 values were determined by probit analysis. Furthermore, simple and multiple regression analyses were carried out by use of the Stat View Software for Macintosh.
Results
Characteristics of the study participants are summarized in Table 11 . The 2 groups differed significantly in body mass index (P <0.0001), waist circumference (P <0.0001), fasting insulin (P <0.002), fasting C-peptide (P <0.0001), HOMA IR index (P <0.0001), systolic blood pressure (P <0.05), triglycerides (P <0.03), and HDL cholesterol (P <0.005). Although all of the obese study participants presented with central obesity, none fulfilled the criteria for the diagnosis of the metabolic syndrome according to the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III) [i.e., the simultaneous presence of 3 of the following variables: waist circumference >88 cm in women, >102 cm in men; HDL-C <1.036 mmol/L (40 mg/dL) in men, <1.295 mmol/L (50 mg/dL) in women; fasting triglycerides >1.695 mmol/L (150 mg/dL); blood pressure >130/85 mmHg; fasting glucose >6.105 mmol/L (110 mg/dL)] (27).
platelet aggregation
Platelet numbers were the same for obese and lean individuals, and platelet response to ADP was similar. In particular, mean (SE) maximal aggregation values in response to 4 μmol/L ADP in obese and lean individuals were 53% (3%) and 51% (4%), respectively (not significant).
Platelet aggregation in response to ADP was reduced by 8-pCPT-cAMP (3–20 min incubation; 10–500 μmol/L) in a concentration-dependent manner both in lean controls and in obese individuals (Fig. 1A1 ; ANOVA for repeated measurements: P <0.0001 for both groups). The antiaggregatory effects of 8-pCPT-cAMP, however, were greater in controls for each concentration of the cyclic nucleotide analog at all experimental times (P <0.05–0.0001). In particular, the mean (SE) IC50 values were lower in controls than in obese-individuals at 10 min [24 ( (7)) vs 252 (41) μmol/L; P <0.0001] and at 20 min [5 ( (1)) vs 123 (33) μmol/L; P <0.01] (Fig. 1B1 ). In individuals with central obesity, no 8-pCPT-cAMP concentration inhibited platelet aggregation to ADP by 50%, so the 8-pCPT-cAMP IC50 for a 3 min platelet exposure could not be calculated. With simple regression analysis, the IC50 value of 8-pCPT-cAMP at 20 min was positively correlated with waist circumference, HOMA IR, HDL cholesterol, triglycerides, and systolic and diastolic blood pressure (Table 22 ). With multiple regression analysis, however, only HOMA IR was significantly correlated with 8-pCPT-cAMP IC50.
In both lean controls and in obese individuals, 8-pCPT-cGMP (3–20 min incubation; 10–500 μmol/L) decreased ADP-induced platelet aggregation in a concentration-dependent manner (ANOVA: P <0.0001) (Fig. 2A2 ). The 8-pCPT-cGMP antiaggregatory effects, however, were greater in controls for each concentration of the cyclic nucleotide analog at all investigated times (P <0.05–0.0001). Furthermore, mean (SE) 8-pCPT-cGMP IC50 values were lower in the control participants than in obese individuals with exposure for 20 min [17 ( (8)) μmol/L vs 172 (43) μmol/L; P <0.01] (Fig. 2B2 ). In individuals with central obesity, it was impossible to calculate the IC50 value with shorter 8-pCPT-cGMP exposure, no concentration inhibited ADP-induced aggregation by 50%. When simple regression analysis was used, the IC50 value of 8-pCPT-cGMP at 20 min was positively correlated with waist circumference, HOMA IR, HDL cholesterol, triglycerides, and systolic and diastolic blood pressure (Table 22 ). With multiple regression analysis, however, only HOMA IR was significantly correlated with 8-pCPT-cGMP IC50.
protein content of pka and pkg
Protein content of PKA and PKG was similar in platelets from obese individuals and from lean controls (Fig. 3A3 ).
phosphorylation of vasp
The total VASP protein content of resting platelets was similar in lean and obese individuals (Fig. 3A3 ). In both lean and obese individuals 8-pCPT-cAMP increased VASP phosphorylation at Ser157 (ANOVA for repeated measurements: P <0.0001 for both groups) (Fig. 3B3 ); the increase was smaller in obese than in lean individuals (significance vs lean individuals: P <0.0001 with 10 μmol/L, P <0.01 with 100 μmol/L, and P <0.05 with 500 μmol/L).
Platelet exposure to 8-pCPT-cGMP increased VASP phosporylation at Ser239 in both lean and obese individuals (ANOVA for repeated measurements: P <0.001 for both groups; Fig. 44 ); the increase was smaller in obese than in lean individuals (significance vs lean individuals: P <0.0001 with 10 μmol/L, P <0.001 with 100 μmol/L, and P <0.01 with 500 μmol/L).
Discussion
This study showed that decreased antiaggregatory action of the cyclic nucleotides cAMP and cGMP in platelets of individuals with central obesity was associated with decreased phosphorylation of VASP at specific sites, reflecting impaired activation of PKA and PKG.
This result strengthens our previous observation that the antiaggregatory action of cAMP and cGMP is reduced in patients with central obesity (11). In fact, in the present study we used highly lipophilic, permeable cyclic nucleotide analogs (i.e., 8-pCPT-cAMP and 8-pCPT-cGMP), which, unlike those previously used (11), do not interfere with phosphodiesterases and are very effective in the activation of specific protein kinases (28).
In obese individuals the inhibitory effect of these analogs on platelet aggregation induced by ADP was much reduced, as shown by the fact that their IC50 values at 20 min were ∼10-fold higher than in controls.
Univariate regression analyses showed that IC50 values of both cyclic nucleotide analogs were correlated with HOMA IR and with other variables such as HDL cholesterol, triglycerides, and systolic and diastolic blood pressure, whose alterations are considered for the diagnosis of metabolic syndrome (27). It should be emphasized, however, that none of the obese individuals met criteria for the diagnosis of metabolic syndrome, because each of them presented at the most only 1 diagnostic feature in addition to central obesity.
When all parameters were pooled together, multiple regression analysis showed that only IC50 values of both cyclic nucleotide analogs remained significantly correlated with HOMA IR, thus suggesting that the molecular defect involved in the resistance to cyclic nucleotides is directly related to insulin resistance.
Our observations may be of interest in the current debate on the causal relationship between insulin resistance and metabolic syndrome (34)(35), because they suggest that insulin resistance per se is directly involved in the pathogenesis of some platelet abnormalities occurring in central obesity, which is a classical component of the metabolic syndrome (27).
Mechanistically, the present study clearly showed impaired activation of the cyclic nucleotide/specific kinase/VASP pathways in individuals with central obesity. Platelets from obese individuals showed a significant decrease in VASP phosphorylation both at Ser157 after exposure to 8-pCPT-cAMP and at Ser239 after exposure to 8-pCPT-cGMP, despite a similar platelet content of PKA, PKG, and VASP proteins. To the best of our knowledge, our study provides the 1st demonstration of an impaired activation of both cyclic nucleotide-dependent protein kinases in obese patients. Abnormalities of these kinases have been previously observed only in patients with neuro-psychiatric disorders (36).
This study, therefore, identified a novel feature of platelet dysfunction occurring in central obesity. Because the molecular defects observed in obese individuals are involved in crucial steps of the control of platelet function (12)(13)(14)(15)(16), the present results may be relevant in explaining resistance not only to the antiaggregatory effects of the cyclic nucleotide analogs but also to other antiaggregatory mediators, which we investigated in previous studies (6)(9)(11). The reduced antiaggregatory effects of insulin, organic nitrates, and prostacyclin, which act through activation of cyclic nucleotide/protein kinase pathways (10)(11), may be explained, at least in part, by an impaired action of the cyclic nucleotides on their specific kinases.
VASP phosphorylation induced by PKA and PKG is known to be relevant to the inhibition of aggregation through modulation of actin polymerization and inhibition of fibrinogen binding to the platelet integrin GP IIb/IIIa (18)(24). The phosphorylation state of VASP in intact cells is regulated to a major extent by serine/threonine protein phosphatases (37); therefore further studies are needed to evaluate whether increased activity of these phosphatases may play a role in the reduced content of phosphorylated VASP in platelets from obese individuals in response to cyclic nucleotide analogs.
In conclusion, the findings of this study further elucidate the complex picture of platelet alterations in obese individuals with insulin resistance. Our previous studies showed resistance to antiaggregatory action of agents due to impaired ability to increase cyclic nucleotide synthesis (6)(7)(8)(9)(10)(11). The present results also show impaired ability of cyclic nucleotides themselves to activate downstream steps of antiaggregation, such as those related to VASP phosphorylation.
These defects, which are closely linked to insulin resistance, could contribute to the pathogenesis of the prothrombotic state described in the insulin resistance syndrome and justify, at least in part, the increased cardiovascular risk attributed to this syndrome (1)(38)(39)(40).
Clinical characteristics of the study participants.1
| Characteristics | Controls | Obese individuals | Significance |
|---|---|---|---|
| No. | 12 | 12 | |
| Men/women (n/n) | 6/6 | 6/6 | |
| Age, years | 34.7 (1.9) | 35.4 (2.1) | NS |
| BMI,2 kg/m2 | 21.5 (0.4) | 32.0 (0.7) | P <0.0001 |
| Waist circumference, cm | 78.5 (3.0) | 106.5 (2.1) | P <0.0001 |
| Glucose, mmol/L | 4.83 (0.14) | 5.18 (0.37) | NS |
| Insulin, pmol/L | 33.7 (3.3) | 217.8 (40.8) | P <0.002 |
| HOMA IR index | 1.7 (0.2) | 4.8 (0.6) | P <0.0001 |
| Fasting C-peptide, ng/mL | 2.17 (0.18) | 3.69 (0.21) | P <0.0001 |
| Systolic blood pressure, mmHg | 118 (2.4) | 125 (2.0) | P <0.05 |
| Diastolic blood pressure, mmHg | 78 (1.3) | 82 (2.1) | NS |
| Triglycerides, mmol/L | 1.1 (0.1) | 1.7 (0.2) | P <0.03 |
| Total cholesterol, mmol/L | 4.8 (0.3) | 5.3 (0.3) | NS |
| HDL cholesterol, mmol/L | 1.6 (0.1) | 1.1 (0.1) | P <0.005 |
| Platelet count in PRP, 109/L | 268 (25) | 248 (18) | NS |
| Characteristics | Controls | Obese individuals | Significance |
|---|---|---|---|
| No. | 12 | 12 | |
| Men/women (n/n) | 6/6 | 6/6 | |
| Age, years | 34.7 (1.9) | 35.4 (2.1) | NS |
| BMI,2 kg/m2 | 21.5 (0.4) | 32.0 (0.7) | P <0.0001 |
| Waist circumference, cm | 78.5 (3.0) | 106.5 (2.1) | P <0.0001 |
| Glucose, mmol/L | 4.83 (0.14) | 5.18 (0.37) | NS |
| Insulin, pmol/L | 33.7 (3.3) | 217.8 (40.8) | P <0.002 |
| HOMA IR index | 1.7 (0.2) | 4.8 (0.6) | P <0.0001 |
| Fasting C-peptide, ng/mL | 2.17 (0.18) | 3.69 (0.21) | P <0.0001 |
| Systolic blood pressure, mmHg | 118 (2.4) | 125 (2.0) | P <0.05 |
| Diastolic blood pressure, mmHg | 78 (1.3) | 82 (2.1) | NS |
| Triglycerides, mmol/L | 1.1 (0.1) | 1.7 (0.2) | P <0.03 |
| Total cholesterol, mmol/L | 4.8 (0.3) | 5.3 (0.3) | NS |
| HDL cholesterol, mmol/L | 1.6 (0.1) | 1.1 (0.1) | P <0.005 |
| Platelet count in PRP, 109/L | 268 (25) | 248 (18) | NS |
Values are expressed as mean (SE).
BMI, Body mass index; NS, not significant.
Clinical characteristics of the study participants.1
| Characteristics | Controls | Obese individuals | Significance |
|---|---|---|---|
| No. | 12 | 12 | |
| Men/women (n/n) | 6/6 | 6/6 | |
| Age, years | 34.7 (1.9) | 35.4 (2.1) | NS |
| BMI,2 kg/m2 | 21.5 (0.4) | 32.0 (0.7) | P <0.0001 |
| Waist circumference, cm | 78.5 (3.0) | 106.5 (2.1) | P <0.0001 |
| Glucose, mmol/L | 4.83 (0.14) | 5.18 (0.37) | NS |
| Insulin, pmol/L | 33.7 (3.3) | 217.8 (40.8) | P <0.002 |
| HOMA IR index | 1.7 (0.2) | 4.8 (0.6) | P <0.0001 |
| Fasting C-peptide, ng/mL | 2.17 (0.18) | 3.69 (0.21) | P <0.0001 |
| Systolic blood pressure, mmHg | 118 (2.4) | 125 (2.0) | P <0.05 |
| Diastolic blood pressure, mmHg | 78 (1.3) | 82 (2.1) | NS |
| Triglycerides, mmol/L | 1.1 (0.1) | 1.7 (0.2) | P <0.03 |
| Total cholesterol, mmol/L | 4.8 (0.3) | 5.3 (0.3) | NS |
| HDL cholesterol, mmol/L | 1.6 (0.1) | 1.1 (0.1) | P <0.005 |
| Platelet count in PRP, 109/L | 268 (25) | 248 (18) | NS |
| Characteristics | Controls | Obese individuals | Significance |
|---|---|---|---|
| No. | 12 | 12 | |
| Men/women (n/n) | 6/6 | 6/6 | |
| Age, years | 34.7 (1.9) | 35.4 (2.1) | NS |
| BMI,2 kg/m2 | 21.5 (0.4) | 32.0 (0.7) | P <0.0001 |
| Waist circumference, cm | 78.5 (3.0) | 106.5 (2.1) | P <0.0001 |
| Glucose, mmol/L | 4.83 (0.14) | 5.18 (0.37) | NS |
| Insulin, pmol/L | 33.7 (3.3) | 217.8 (40.8) | P <0.002 |
| HOMA IR index | 1.7 (0.2) | 4.8 (0.6) | P <0.0001 |
| Fasting C-peptide, ng/mL | 2.17 (0.18) | 3.69 (0.21) | P <0.0001 |
| Systolic blood pressure, mmHg | 118 (2.4) | 125 (2.0) | P <0.05 |
| Diastolic blood pressure, mmHg | 78 (1.3) | 82 (2.1) | NS |
| Triglycerides, mmol/L | 1.1 (0.1) | 1.7 (0.2) | P <0.03 |
| Total cholesterol, mmol/L | 4.8 (0.3) | 5.3 (0.3) | NS |
| HDL cholesterol, mmol/L | 1.6 (0.1) | 1.1 (0.1) | P <0.005 |
| Platelet count in PRP, 109/L | 268 (25) | 248 (18) | NS |
Values are expressed as mean (SE).
BMI, Body mass index; NS, not significant.
(A), concentration- and time-dependent effects of the cell permeable cAMP analog 8-pCPT-cAMP (10–500 μmol/L) on ADP-induced platelet aggregation in controls (n = 12) and obese individuals (n = 12) after 3-, 10-, and 20-min incubation.
Data [mean (SE), n = 12] are expressed as percentage of the aggregation values in absence of the cyclic nucleotide analog. Inhibition of platelet response was significantly lower in obese individuals, as shown in the Fig. (*P <0.05, **P <0.01, and ***P <0.0001). (B), IC50 values [mean (SE), n = 12] of 8-pCPT-cAMP (μmol/L) for ADP-induced aggregation after 20-min incubation in controls (n = 12) and obese individuals (n = 12). Significance in the Fig.: **P <0.01.
Simple and multiple regression analysis concerning the relation between cyclic nucleotide IC50 values and different variables measured in controls and obese individuals.
| IC50 value of 8-pCPT-cAMP | IC50 value of 8-pCPT-cGMP | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Regression analysis | Simple | Multiple | Simple | Multiple | ||||||||||||||
| r | P | β | t | P | r | P | β | t | P | |||||||||
| Waist circumference | 0.796 | 0.001 | −0.035 | −0.108 | 0.917 | 0.786 | 0.001 | −0.109 | −0.269 | 0.797 | ||||||||
| BMI1 | 0.858 | 0.0001 | −0.197 | −0.525 | 0.619 | 0.839 | 0.0001 | −0.362 | −0.779 | 0.466 | ||||||||
| HOMA IR | 0.944 | 0.0001 | 1.157 | 4.079 | 0.007 | 0.929 | 0.0001 | 1.203 | 3.416 | 0.014 | ||||||||
| HDL cholesterol | −0.531 | 0.051 | 0.258 | 1.789 | 0.124 | −0.534 | 0.049 | 0.215 | 1.203 | 0.274 | ||||||||
| Triglycerides | 0.747 | 0.002 | 0.149 | 0.584 | 0.581 | 0.744 | 0.002 | 0.341 | 1.077 | 0.323 | ||||||||
| Systolic blood pressure | 0.611 | 0.020 | −0.014 | −0.059 | 0.955 | 0.605 | 0.022 | 0.141 | 0.472 | 0.654 | ||||||||
| Diastolic blood pressure | 0.667 | 0.009 | 0.128 | 0.626 | 0.554 | 0.628 | 0.016 | −0.057 | −0.224 | 0.830 | ||||||||
| R2 | 0.947 | 0.918 | ||||||||||||||||
| IC50 value of 8-pCPT-cAMP | IC50 value of 8-pCPT-cGMP | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Regression analysis | Simple | Multiple | Simple | Multiple | ||||||||||||||
| r | P | β | t | P | r | P | β | t | P | |||||||||
| Waist circumference | 0.796 | 0.001 | −0.035 | −0.108 | 0.917 | 0.786 | 0.001 | −0.109 | −0.269 | 0.797 | ||||||||
| BMI1 | 0.858 | 0.0001 | −0.197 | −0.525 | 0.619 | 0.839 | 0.0001 | −0.362 | −0.779 | 0.466 | ||||||||
| HOMA IR | 0.944 | 0.0001 | 1.157 | 4.079 | 0.007 | 0.929 | 0.0001 | 1.203 | 3.416 | 0.014 | ||||||||
| HDL cholesterol | −0.531 | 0.051 | 0.258 | 1.789 | 0.124 | −0.534 | 0.049 | 0.215 | 1.203 | 0.274 | ||||||||
| Triglycerides | 0.747 | 0.002 | 0.149 | 0.584 | 0.581 | 0.744 | 0.002 | 0.341 | 1.077 | 0.323 | ||||||||
| Systolic blood pressure | 0.611 | 0.020 | −0.014 | −0.059 | 0.955 | 0.605 | 0.022 | 0.141 | 0.472 | 0.654 | ||||||||
| Diastolic blood pressure | 0.667 | 0.009 | 0.128 | 0.626 | 0.554 | 0.628 | 0.016 | −0.057 | −0.224 | 0.830 | ||||||||
| R2 | 0.947 | 0.918 | ||||||||||||||||
BMI, Body mass index.
Simple and multiple regression analysis concerning the relation between cyclic nucleotide IC50 values and different variables measured in controls and obese individuals.
| IC50 value of 8-pCPT-cAMP | IC50 value of 8-pCPT-cGMP | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Regression analysis | Simple | Multiple | Simple | Multiple | ||||||||||||||
| r | P | β | t | P | r | P | β | t | P | |||||||||
| Waist circumference | 0.796 | 0.001 | −0.035 | −0.108 | 0.917 | 0.786 | 0.001 | −0.109 | −0.269 | 0.797 | ||||||||
| BMI1 | 0.858 | 0.0001 | −0.197 | −0.525 | 0.619 | 0.839 | 0.0001 | −0.362 | −0.779 | 0.466 | ||||||||
| HOMA IR | 0.944 | 0.0001 | 1.157 | 4.079 | 0.007 | 0.929 | 0.0001 | 1.203 | 3.416 | 0.014 | ||||||||
| HDL cholesterol | −0.531 | 0.051 | 0.258 | 1.789 | 0.124 | −0.534 | 0.049 | 0.215 | 1.203 | 0.274 | ||||||||
| Triglycerides | 0.747 | 0.002 | 0.149 | 0.584 | 0.581 | 0.744 | 0.002 | 0.341 | 1.077 | 0.323 | ||||||||
| Systolic blood pressure | 0.611 | 0.020 | −0.014 | −0.059 | 0.955 | 0.605 | 0.022 | 0.141 | 0.472 | 0.654 | ||||||||
| Diastolic blood pressure | 0.667 | 0.009 | 0.128 | 0.626 | 0.554 | 0.628 | 0.016 | −0.057 | −0.224 | 0.830 | ||||||||
| R2 | 0.947 | 0.918 | ||||||||||||||||
| IC50 value of 8-pCPT-cAMP | IC50 value of 8-pCPT-cGMP | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Regression analysis | Simple | Multiple | Simple | Multiple | ||||||||||||||
| r | P | β | t | P | r | P | β | t | P | |||||||||
| Waist circumference | 0.796 | 0.001 | −0.035 | −0.108 | 0.917 | 0.786 | 0.001 | −0.109 | −0.269 | 0.797 | ||||||||
| BMI1 | 0.858 | 0.0001 | −0.197 | −0.525 | 0.619 | 0.839 | 0.0001 | −0.362 | −0.779 | 0.466 | ||||||||
| HOMA IR | 0.944 | 0.0001 | 1.157 | 4.079 | 0.007 | 0.929 | 0.0001 | 1.203 | 3.416 | 0.014 | ||||||||
| HDL cholesterol | −0.531 | 0.051 | 0.258 | 1.789 | 0.124 | −0.534 | 0.049 | 0.215 | 1.203 | 0.274 | ||||||||
| Triglycerides | 0.747 | 0.002 | 0.149 | 0.584 | 0.581 | 0.744 | 0.002 | 0.341 | 1.077 | 0.323 | ||||||||
| Systolic blood pressure | 0.611 | 0.020 | −0.014 | −0.059 | 0.955 | 0.605 | 0.022 | 0.141 | 0.472 | 0.654 | ||||||||
| Diastolic blood pressure | 0.667 | 0.009 | 0.128 | 0.626 | 0.554 | 0.628 | 0.016 | −0.057 | −0.224 | 0.830 | ||||||||
| R2 | 0.947 | 0.918 | ||||||||||||||||
BMI, Body mass index.
(A), concentration- and time-dependent effects of the cell permeable cGMP analog 8-pCPT-cGMP (10–500 μmol/L) on ADP-induced platelet aggregation in controls (n = 12) and obese individuals (n = 12) after 3-, 10-, and 20-min incubation.
Data [mean (SE), n = 12] are expressed as percentage of the aggregation values in absence of the cyclic nucleotide analog. Inhibition of platelet response was significantly lower in obese individuals as shown in the Fig. (*P <0.05, **P <0.01, and ***P <0.0001). (B), IC50 values [mean (SE), n = 12] of 8-pCPT-cGMP (μmol/L) for ADP-induced aggregation after 20-min incubation in controls (n = 12) and obese individuals (n = 12). Significance in the Fig.: **P <0.01.
(A), expression of PKG, PKA, and VASP in platelet lysates from both controls and obese individuals.
The results, obtained by Western blot with antibodies against the specific proteins, are representative of duplicate experiments carried out in 9 individuals. By densitometric analysis, no difference in protein expression was shown in platelets from obese individuals in comparison with lean controls. (B), expression of the protein VASP phosphorylated at Ser157 (PKA-dependent) in platelet lysates from both controls (n = 12) and obese individuals (n = 12) after 10-min incubation with the cell permeable cAMP analog 8-pCPT-cAMP (10–500 μmol/L). The densitometric analysis carried out on the bands obtained by Western blot showed a reduced phosphorylation in platelets from obese individuals in comparison with lean controls. Data are expressed as mean (SE), n = 12. In both lean and obese individuals 8-pCPT-cAMP induced a significant concentration-dependent VASP phosphorylation (ANOVA <0.0001); the effect in obese individuals, however, was lower than in lean individuals as shown in the Fig. (*P <0.05, **P <0.01, and ***P <0.0001).
Expression of the protein VASP phosphorylated at Ser239 (PKG-dependent) in platelet lysates from both controls (n = 12) and obese individuals (n = 12) after 10-min incubation with the cell permeable cGMP analog 8-pCPT-cGMP (10–500 μmol/L).
The densitometric analysis carried out on the bands obtained by Western blot showed a reduced phosphorylation in platelets from obese individuals in comparison with lean controls. Data are expressed as mean (SE), n = 12. In both lean and obese individuals 8-pCPT-cGMP induced a significant concentration-dependent VASP phosphorylation (ANOVA <0.001); the effect in obese individuals, however, was lower than in lean individuals as shown in the Fig. (*P <0.01, **P <0.001, and ***P <0.0001).
Nonstandard abbreviations: PKG, protein kinase G; PKA, protein kinase A; VASP, vasodilator-stimulated phosphoprotein; GP IIb/IIIa, glycoprotein IIb/IIIa; 8-pCPT-cAMP, 8-(4-Chlorophenylthio)-cAMP; 8-pCPT-cGMP, 8-(4-Chlorophenylthio)-cGMP; HOMA IR, Homeostasis Model Assessment Index of Insulin Resistance; PRP, platelet-rich plasma; PPP, platelet-poor plasma; IC50, half-maximal inhibitory concentration.
Grant/funding support: This study was supported by a research grant from Italian Ministero dell’Istruzione, Università e Ricerca (MIUR) COFIN 2004 within the project “The molecular basis of insulin resistance and their importance in the pathogenesis of the alterations of the vessel wall”, Local Coordinator: Prof. Giovanni Anfossi, National Coordinator: Prof. Amalia Bosia and by a research grant from Regione Piemonte (to G.A.).
Financial disclosures: None declared.
Acknowledgements: We thank Mrs. Anna Baker for her linguistic assistance.
Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis.
McGill HC, McMahan CA, Herderick EE, Zieske AW, Malcolm GT, Tracy RE, et al. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Obesity accelerates the progression of coronary atherosclerosis in young men.
Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition.
Massberg S, Brand K, Gruner S, Page S, Muller E, Muller I, et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation.
Trovati M, Mularoni E, Burzacca S, Ponziani MC, Massucco P, Mattiello L, et al. Impaired insulin-induced platelet anti-aggregating effect in obesity and in obese NIDDM patients.
Trovati M, Anfossi G. Insulin, insulin-resistance, and platelet function: similarities with insulin effects on cultured smooth muscle cells.
Trovati M, Anfossi G. Influence of insulin and of insulin resistance on platelet and vascular smooth muscle cell function.
Anfossi G, Mularoni EM, Burzacca S, Ponziani MC, Massucco P. Mattiello L, et al. Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM.
Anfossi G, Mularoni E, Burzacca S, Ponziani MC, Massucco P, Mattiello L, et al. Impaired platelet sensitivity to the anti-aggregating effects of adenosine in obesity and obese non-insulin-dependent diabetes mellitus. Belfiore F Lorenzi M Molinatti GM Porta M eds.
Anfossi G, Russo I, Massucco P, Mattiello L, Doronzo G, De Salve A, et al. Impaired synthesis and action of antiaggregating cyclic nucleotides in platelets from obese subjects: possible role in platelet hyperactivation in obesity.
Pfeifer A, Ruth P. Structure and function of cGMP-dependent protein kinases.
Schwarz UR, Walter U, Eigenthaler M. Taming platelets with cyclic nucleotides.
Jensen BO, Selheim F, Doskeland SO, Gear ARL, Holmsen H. Protein kinase A mediates inhibition of the thrombin-induced platelet shape change by nitric oxide.
Antl M, von Bruhl ML, Eiglsperger C, Werner M, Konrad I, Kocher T, et al. IRAG mediates NO/cGMP-dependent inhibition of platelet aggregation and thrombus formation.
Yamanishi J, Kawahara Y, Fukuzaki H. Effect of cyclic AMP on cytoplasmic free calcium in human platelets stimulated by thrombin: direct measurement with quin-2.
Kawahara Y, Yamanishi J, Fukuzaki H. Inhibitory action of guanosine 3′,5′ monophosphate on thrombin-induced calcium mobilization in human platelets.
Horstrup K, Jablonka B, Honig-Liedl P, Just M, Kochsiek K, Walter U. Phosphorylation of focal adhesion vasodilator-stimulated phosphoprotein at Ser157 in intact human platelets correlates with fibrinogen receptor inhibition.
Bearer EL, Prakash JM, Manchester RD, Allen PG. VASP protects actin filaments from gelsolin: an in vitro study with implications for platelet actin reorganizations.
Li Z, Xi X, Gu M, Feil R, Ye RD, Eigenthaler M, et al. A stimulatory role for cGMP-dependent protein kinase in platelet activation.
Li Z, Zhang G, Feil R, Han J, Du X. Sequential activation of p38 and ERK pathways by cGMP-dependent protein kinase leading to activation of the platelet integrin alphaIIb beta3.
Waldmann R, Nieberding M, Walter U. Vasodilator-stimulated protein phosphorylation in platelets is mediated by cAMP- and cGMP-dependent protein kinases.
Butt E, Abel K, Krieger M, Palm D, Hoppe V, Walter U. cAMP- and cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein (VASP) in vitro and in intact human platelets.
Hauser W, Knobeloch KP, Eigenthaler M, Gambaryan S, Krenn V, Geiger J, et al. Megakaryocyte hyperplasia and enhanced agonist-induced platelet activation in vasodilator-stimulated phosphoprotein knockout mice.
Nolte C, Eigenthaler M, Horstrup K, Honig-Liedl P, Walter U. Synergistic phosphorylation of the focal adhesion-associated vasodilator-stimulated phosphoprotein in intact human platelets in response to cGMP- and cAMP-elevating platelet inhibitors.
Resnick LM. Ionic basis of hypertension, insulin resistance, vascular disease, and related disorders: the mechanism of “Syndrome X”.
. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report.
Geiger J, Nolte C, Butt E, Sage SO, Walter U. Role of cGMP and cGMP-dependent protein kinase in nitrovasodilator inhibition of agonist-evoked calcium elevation in human platelets.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentration in man.
Haffner SM, Miettinen H, Stern MP. Homeostasis model in the San Antonio Heart Study.
Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal.
Dey NB, Boerth NJ, Murphy-Ullrich JE, Chang PL, Prince CW, Lincoln TM. Cyclic GMP-dependent protein kinase inhibits osteopontin and thrombospondin production in rat aortic smooth muscle cells.
Kahn R, Buse J, Ferrannini E, Stern M, . American Diabetes Association; European Association for the Study of Diabetes. The Metabolic Syndrome: time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.
Kim SH, Reaven GM. The metabolic syndrome: one step forward, two steps back.
Tardito D, Maina G, Tura GB, Bogetto F, Pioli R, Ravizza L, et al. The cAMP-dependent protein kinase substrate Rap1 in platelets from patients with obsessive compulsive disorder or schizophrenia.
Abel K, Mieskes G, Walter U. Dephosphorylation of the focal adhesion protein VASP in vitro and in intact human platelets.
Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome.
Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes.
